Kayyem Jon Faiz Insider Trading Activity

Average Profitability
22.31%
Insider Buys Quantity
4
Insider Buys Sum
$1.36M
Insider Sells Quantity
4
Insider Sells Sum
$1.07M

Insider Activity of Kayyem Jon Faiz

According to the SEC Form 4 filings, Kayyem Jon Faiz, being in a position of

  1. director at Inhibrx Biosciences Inc.,
    оver the last 12 months, has bought 15000 shares for $1.57M, and sold 0 shares,
    over all time since 2022-10-21, has bought 68593 shares for $2.33M, and sold 38000 shares for $1.07M.

Biography of Kayyem Jon Faiz

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $1,567,5803100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2026-09-23PurchaseInhibrx Biosciences Inc.
INBX
director
5,000
0.034%
$100.00$500,000-6.93%
2026-09-16PurchaseInhibrx Biosciences Inc.
INBX
director
5,000
0.0335%
$100.00$500,000-6.86%
2026-09-08PurchaseInhibrx Biosciences Inc.
INBX
director
5,000
0.0317%
$113.52$567,580-15.76%
2024-11-20PurchaseInhibrx Biosciences, Inc.
INBX
director
18,750
0.1292%
$14.19$266,102+5.59%
2024-11-19PurchaseInhibrx Biosciences, Inc.
INBX
director
34,843
0.2402%
$14.23$495,708+3.39%
2023-01-23SaleInhibrx, Inc.
INBX
director
9,500
0.0235%
$25.26$239,999-10.6%
2022-12-21SaleInhibrx, Inc.
INBX
director
9,500
0.0222%
$27.02$256,679-14.89%
2022-11-21PurchaseBiodesix, Inc.
BDSX
director
173,913
0.2661%
$1.15$200,000+22.31%
2022-11-21PurchaseBiodesix, Inc.
BDSX
director
347,826
0.5323%
$1.15$400,000+22.31%
2022-11-21SaleInhibrx, Inc.
INBX
director
9,500
0.0217%
$29.89$283,972-23.93%
2022-10-21SaleInhibrx, Inc.
INBX
director
9,500
0.0213%
$30.13$286,232-23.69%
Total: 11
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.